Anxiety and depression symptoms in adults and elderly in post-percutaneous coronary intervention

Abstract Backgroud: It’s known that coronary heart disease (CHD) patients after percutaneous coronary intervention (PCI) was significantly associated with anxiety and depression symptoms. Several studies have showed that Xinkeshu tablet (XKS), a kind of Chinese herbal medicine (CHM) , could effectively improve post-PCI postoperative mood disorders in CHD patients. However, the intensity of evidence has been poor, limiting the further clinical application of XKS to patients above. This systematic review and meta-analysis will assess studies of the effectiveness and safety of XKS in CHD patients with anxiety and depression symptoms after PCI. Methods: A systematic literature search for articles up to July 2020 will be performed in following electronic databases: PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP) Database, Chinese Biomedical Database (CBM), Chinese Biomedical Literature Service System (SinoMed) and Wanfang Database. Inclusion criteria are randomized controlled trials of XKS applied on patients with CHD and depression. The primary outcome measures will be CHD-related clinical evaluation (frequency of acute attack angina, severity of angina pectoris, electrocardiographic changes, amount of nitroglycerin) and the scores or reducing fractions of depressive and anxiety measuring scales (the Hospital Anxiety / Depression Scale or other widely used anxiety / depression scale). The safety outcome measures will be adverse events, liver and kidney function. RevMan 5.3 software will be used for data synthesis, sensitivity analysis, subgroup analysis and risk of bias assessment. A funnel plot will be developed to evaluate reporting bias. Stata 12.0 will be used for meta-regression and Egger tests. We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to assess the quality of evidence. Discussion: This study will provide a high-quality synthesis of the effects and safety of XKS for CHD patients with anxiety and depression symptoms after PCI. Ethics and dissemination This systematic review does not require ethics approval and will be submitted to a peer-reviewed journal. Trial registration number PROSPERO CRD42019131346.

Download Full-text

Effectiveness and safety of Xinkeshu on coronary artery disease patients combined with anxiety and depression symptoms after percutaneous coronary intervention

Medicine ◽

10.1097/md.0000000000027912 ◽

2021 ◽

Vol 100 (46) ◽

pp. e27912

Author(s):

Mingtai Chen ◽

Guofu Zhong ◽

Ling Men ◽

Qiang Liu ◽

Jienan Luan

Keyword(s):

Coronary Artery Disease ◽

Percutaneous Coronary Intervention ◽

Coronary Artery ◽

Coronary Intervention ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Percutaneous Coronary ◽

Artery Disease

Download Full-text

Increased prevalence of anxiety and depression symptoms in patients with coronary artery disease before and after percutaneous coronary intervention treatment

BMC Psychiatry ◽

10.1186/s12888-016-0972-9 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 28

Author(s):

Guoqiang Gu ◽

Yaqing Zhou ◽

Ying Zhang ◽

Wei Cui

Keyword(s):

Coronary Artery Disease ◽

Percutaneous Coronary Intervention ◽

Coronary Artery ◽

Coronary Intervention ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Intervention Treatment ◽

Percutaneous Coronary ◽

Before And After ◽

Artery Disease

Download Full-text

Associations between macrophage inhibitor factor, anxiety and depression in patients with ST-segment elevation myocardial infarction

Ukrainian Journal of Cardiology ◽

10.31928/1608-635x-2019.3.4552 ◽

2019 ◽

Vol 26 (3) ◽

pp. 45-52

Author(s):

O. V. Petyunina ◽

M. P. Kopytsya ◽

О. V. Skrynnik

Keyword(s):

Myocardial Infarction ◽

Percutaneous Coronary Intervention ◽

Coronary Intervention ◽

Anxiety And Depression ◽

Control Group ◽

St Segment Elevation ◽

Segment Elevation Myocardial Infarction ◽

St Segment ◽

Percutaneous Coronary ◽

Anxiety Depression

The aim – to investigate associations between macrophage inhibitory factor (MIF) and anxiety, depression and stress in patients with ST-segment elevation myocardial infarction (STEMI). Materials and methods. 73 patients with STEMI with TIMI-III aged 58.37±10.34 were enrolled in the study. Revascularization tactics distribution was the following: 43 (58.9 %) patients underwent primary percutaneous coronary intervention using bare-metal coronary stent, 30 (41.1 %) – pre-hospital thrombolysis with subsequent percutaneous coronary intervention within12 hours. Echocardiography was done during the period of hospitalization. Serum MIF was studied using the enzyme linked immunoassay method. Anxiety, depression and stress were determined with DASS-21 questionnaire. Results and discussion. When comparing the median values of the MIF level in STEMI patients, a statistically significant increase in the MIF concentration relative to control group (2582.80 [1308.40–4122.20] and 573.75 [397.80–1016.75] ng/ml, p<0.001). It evidences the activation of the formation of MIF after the index event. Positive correlation was determined between the level of MIF, the level of troponin I (r=0.33; р=0.045) and blood leukocytes (r=0.36; р=0.039) that confirms its involvement into inflammation and necrosis processes. The univariant and multivariate analysis revealed the effect of the degree of depression and anxiety growth on the DASS-21 questionnaire (p=0.0138 and p=0.0050, respectively) on the increasing of the MIF. Conclusions. The data obtained confirm the relationship between the MIF and anxiety and depression prior the onset of myocardial infarction, indicating their influence on the processes of inflammation.

Download Full-text